Company file · A

Agilent Technologies

Life Sciences and Diagnostics Markets was Agilent Technologies' fastest-growing segment in FY2025, up 10.5%

Revenue rose 6.7% to $6.9B in FY2025, from $6.5B in FY2024. Net income rose 1.1% to $1.3B. Agilent CrossLab was the largest segment, at 42% of revenue.

Prepared from SEC filings · Latest annual report: 10-K for FY2025 (filed Dec 22, 2025) · Latest quarter: 10-Q for the quarter ended Jul 31, 2026 (filed Sep 1, 2026) · Data pulled Nov 11, 2026

Key facts

Agilent Technologies (NYSE: A) closed fiscal 2025 on Oct 31, 2025 with revenue of $6.9B, up 6.7% from a year before; net income came to $1.3B, up 1.1%. Its newest quarterly report covers the three months to Jul 31, 2026: revenue of $1.9B, up 8.1% on the same stretch of the prior year, and net income of $362M. Broken down by segment, Agilent CrossLab led with 42% of fiscal 2025 revenue. Sources: 10-K for fiscal 2025 (filed Dec 22, 2025) and 10-Q for the quarter ended Jul 31, 2026 (filed Sep 1, 2026).

Revenue$6.9BFY2025 · +6.7% vs FY2024

Net income$1.3BFY2025 · +1.1% vs FY2024

Operating cash flow$1.6BFY2025 · −11.0% vs FY2024

Cash & equivalents$1.8Bat Jul 31, 2026 · −1.7% vs FY2025 end

Total debt$3.9Bat Jul 31, 2026 · +17.7% vs FY2025 end

Diluted shares285MFY2025 avg · −2.1% vs FY2024

Revenue and net income, three fiscal yearsBy fiscal year, $bn

RevenueNet income

Source: 10-K FY2025, filed Dec 22, 2025

Quarterly revenue: fiscal 2026 vs a year earlierFiscal Q1–Q3, $bn (each quarter from that quarter's 10-Q)

FY2025FY2026

Source: 10-Q filed Mar 3, 2026 · 10-Q filed Jun 1, 2026 · 10-Q filed Sep 1, 2026

How it makes money

By segment, FY2025

LineAmountSharevs FY2024
Agilent CrossLab$2.9B42%+5.9%
Life Sciences and Diagnostics Markets$2.7B39%+10.5%
Applied Markets$1.3B19%+1.3%

Source: 10-K FY2025, XBRL breakdown

By segment in FY2025: Agilent CrossLab (42%), Life Sciences and Diagnostics Markets (39%) and Applied Markets (19%), as shares of total revenue. Total revenue was $6.9B.

By segment: three-year mixShare of the total each fiscal year

FY2023

39%41%20%

FY2024

42%38%20%

FY2025

42%39%19%

Agilent CrossLabLife Sciences and Diagnostics MarketsApplied Markets

Source: 10-K FY2025

By product or service, FY2025

Products$4.9B71%+5.8%

Service, Other$2.0B29%+9.0%

Share is of the FY2025 total; the last column is the change from FY2024.

Learn more: Revenue vs. net income · Gross, operating and net margin

What changed last quarter

How the quarter compared with a year earlier

Comparing Q3 FY2026 (May to Jul 2026) compared with Q3 FY2025 (May to Jul 2025)

Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.

Q3 FY2026Q3 FY2025

Company

Revenue

$1.9B Q3 FY2026

$1.7B Q3 FY2025

8.1% increase

Net income

$362M Q3 FY2026

$336M Q3 FY2025

7.7% increase

Source: Agilent Technologies 10-Q for the quarter ended Jul 31, 2026, filed Sep 1, 2026

By segment

Agilent CrossLab

$786M Q3 FY2026

$744M Q3 FY2025

5.6% increase

Life Sciences and Diagnostics Markets

$746M Q3 FY2026

$670M Q3 FY2025

11.3% increase

Applied Markets

$346M Q3 FY2026

$324M Q3 FY2025

6.8% increase

Source: Agilent Technologies 10-Q for the quarter ended Jul 31, 2026, filed Sep 1, 2026

Cash & equivalents $1.8B at Jul 31, 2026, vs $1.8B at FY2025 end.
Total debt $3.9B at Jul 31, 2026, vs $3.4B at FY2025 end.
Operating cash flow, first 9 months of fiscal 2026: $1.1B vs $1.0B a year earlier.

The bull case and the bear case

The bull case

Revenue rose 6.7% in FY2025 to $6.9B, from $6.5B a year earlier. 10-K, FY2025
Net income rose 1.1% in FY2025 to $1.3B, from $1.3B. 10-K, FY2025
Diluted shares fell 2.1% in FY2025, so each share represents a larger slice of profit. 10-K, FY2025
Revenue in the quarter ended Jul 31, 2026 was $1.9B, up 8.1% on a year earlier. 10-Q, quarter ended Jul 31, 2026

The bear case

Operating cash flow fell 11.0% in FY2025 to $1.6B. 10-K, FY2025
The company's own risk factors are in Item 1A of its 10-K. Risks common in this industry include regulation; pricing and reimbursement; competition. 10-K, Item 1A

What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.

What the company does

Agilent Technologies is in the life sciences tools & services industry, part of the health care sector. The SEC files it under Laboratory Analytical Instruments.

Agilent Technologies reports 3 segments: Agilent CrossLab, Life Sciences and Diagnostics Markets and Applied Markets.

Its fiscal year ends in October; the latest, FY2025, ended Oct 31, 2025.

Source: 10-K, Item 1 Business

Risks common in this industry

These are general risks for companies in the life sciences tools & services industry. They are not a summary of Agilent Technologies’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.

RegulationApprovals, safety rules and government oversight shape what it can sell and how.
Pricing and reimbursementPayers, insurers and governments influence what it can charge.
CompetitionNew treatments, generics and rival products can take share.
LitigationProduct liability and other legal claims can lead to costs.
SupplyManufacturing and supplier problems can interrupt products.

Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)

Three years of key numbers

Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.

US$	FY2023	FY2024	FY2025
Revenue	$6.8B	$6.5B	$6.9B
Net income	$1.2B	$1.3B	$1.3B
Operating cash flow	$1.8B	$1.8B	$1.6B
Cash & equivalents (year end)	$1.6B	$1.3B	$1.8B
Total debt (year end)	$2.7B	$3.4B	$3.4B
Diluted shares	296M	291M	285M

Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
Total debt: Short-term borrowings plus long-term debt, at carrying value.
Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.

Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator

Explainers for this page

Plain-English guides to terms this file uses, with real numbers from filings.

About these numbers

Recent filings

Form	Filed	Period
10-Q	Sep 1, 2026	Jul 31, 2026
10-Q	Jun 1, 2026	Apr 30, 2026
10-Q	Mar 3, 2026	Jan 31, 2026
DEF 14A	Feb 6, 2026	Mar 18, 2026
10-K	Dec 22, 2025	Oct 31, 2025

Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters

Common questions about Agilent Technologies

How does Agilent Technologies make money?

Fiscal 2025 revenue: $6.9B. By segment in FY2025: Agilent CrossLab (42%), Life Sciences and Diagnostics Markets (39%) and Applied Markets (19%), as shares of total revenue. Total revenue was $6.9B. Source: 10-K for fiscal 2025, filed Dec 22, 2025.

What was Agilent Technologies's revenue in fiscal 2025?

$6.9B, up 6.7% from fiscal 2024 ($6.5B). The year ended Oct 31, 2025; for fiscal 2023 the figure was $6.8B. Source: 10-K for fiscal 2025, filed Dec 22, 2025.

Is Agilent Technologies profitable?

Net income was $1.3B in fiscal 2025 (up 1.1%; fiscal 2024 was $1.3B). That counts as a GAAP profit. The latest quarter, ended Jul 31, 2026: net income was $362M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2025, filed Dec 22, 2025.

What did Agilent Technologies report in its latest quarterly filing?

For the three months to Jul 31, 2026: revenue $1.9B (up 8.1% from $1.7B) and net income $362M (up 7.7% from $336M). Source: 10-Q for the quarter ended Jul 31, 2026, filed Sep 1, 2026.

How much cash and debt does Agilent Technologies have?

As of Jul 31, 2026: $1.8B of cash and cash equivalents, $3.9B of total debt. Total debt here is short-term borrowings plus long-term debt, at carrying value. Source: 10-Q filed Sep 1, 2026.

What are the main risks Agilent Technologies faces?

Agilent Technologies's own risk factors are in Item 1A of its 10-K for fiscal 2025, filed Dec 22, 2025. Risks that are common among companies in the life sciences tools & services industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.

Where do these Agilent Technologies numbers come from?

The 10-K filed Dec 22, 2025 (fiscal 2025) and the 10-Q filed Sep 1, 2026 (quarter ended Jul 31, 2026), as published in the SEC's XBRL data. Click any number to open the filing it came from. Methodology explains how fiscal years and missing numbers are handled.

Tracked funds that report owning Agilent Technologies

Citadel Advisors: 1,101,501 shares, reported value $146.3M at Jun 30, 2026 (−38.9% in shares since the filing for Mar 31, 2026). Form 13F filed Sep 2, 2026.
Millennium Management: 91,938 shares, reported value $12.2M at Jun 30, 2026 (−86.6% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Two Sigma Investments: 23,537 shares, reported value $3.1M at Jun 30, 2026 (−96.5% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Bridgewater Associates: 22,889 shares, reported value $3.0M at Jun 30, 2026 (−68.9% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.

From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.

Disclosures

Editor holdings in A: The editor holds no position in Agilent Technologies (A). As of Nov 11, 2026.
Trading rule: The editor does not buy or sell A from 3 days before to 3 days after this page is published or substantively updated.
Compensation: Nobody paid for this page. No affiliate links on this page.
Sources: The company's SEC filings, linked next to each number or, for charts, in the source line under them.
Last updated: Nov 5, 2026

General education, the same for every reader. Not a recommendation to buy, sell or hold A, and it doesn't consider your situation.

Compare with peers

Company	Fiscal year	Revenue	Revenue growth	Net income
Agilent TechnologiesA	FY2025	$6.9B	+6.7%	$1.3B
Thermo FisherTMO	FY2025	$44.6B	+3.9%	$6.7B
DanaherDHR	FY2025	$24.6B	+2.9%	$3.6B
WatersWAT	FY2025	$3.2B	+7.0%	$643M
IQVIAIQV	FY2025	$16.3B	+5.9%	$1.4B

Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.

More company files

New to filings? Learn has plain-English explainers and Tools has calculators. Methodology & Disclosures covers where every number comes from.